Abstract
BIX01294 (Bix) is a known euchromatic histone-lysine N-methyltransferase 2 inhibitor, typically used to suppress cancer cell survival. However, this study reveals that sequential treatment with low-dose Bix notably increases glioblastoma cell migration and metastasis. U251 cells treated sequentially with low-dose Bix exhibited characteristic changes in critical epithelial-mesenchymal transition (EMT) markers and increased expression of cancer stem cell-associated markers (SOX2, OCT4, CD133). These findings suggest that chronic exposure to sub-lethal doses of Bix enhances the invasive potential of glioblastoma by regulating EMT-associated gene expression and altering stem cell properties.
Introduction
Glioblastoma multiforme (GBM) remains one of the most lethal and difficult-to-treat primary brain tumors due to its highly infiltrative nature. While therapeutic strategies often focus on inducing cell death, the epigenetic landscape of these tumors offers complex challenges. BIX01294 (Bix) is a small molecule inhibitor of G9a, an enzyme that methylates histone H3 lysine 9 (H3K9), a modification associated with gene silencing. While high doses of Bix are cytotoxic, the effects of persistent, low-level exposure—common in regions of poor drug penetration—are less understood.
Methods and Experimental Design
The study utilized the U251 human glioblastoma cell line to compare two distinct treatment protocols:
- Single Treatment (SBT): Cells received a one-time dose of Bix ranging from 1 to 10 µM.
- Sequential Treatment (SeBT): Cells were treated with a low dose (1 µM) of Bix every two days over a 14-day period to simulate chronic accumulation.
Researchers evaluated cell viability, migration, invasion, and "stemness" through transwell assays and neurosphere formation tests. Molecular changes were tracked using RT-qPCR and Western blotting for EMT and stem cell markers.
Key Results
The Dosage Paradox: Survival vs. Transformation
While higher doses of Bix in the SBT group significantly reduced cell survival and induced markers of apoptosis and autophagy (such as cleaved PARP1 and LC3B-II), the sequential low-dose treatment (SeBT) had negligible effects on cell viability. Instead, SeBT induced a profound phenotypic shift.
Activation of the EMT Program
The most striking finding was the induction of the epithelial-mesenchymal transition (EMT) in SeBT cells. Western blot analysis showed a significant decrease in the epithelial marker E-cadherin, coupled with a marked increase in mesenchymal markers, including N-cadherin, β-catenin, and the transcription factor Slug.
Enhanced Migration and Stemness
Functionally, SeBT cells exhibited a 12-fold increase in migratory capacity and a 2.5-fold increase in invasive potential. Furthermore, these cells showed upregulated expression of stem cell markers SOX2, OCT4, and CD133, and demonstrated a significantly higher capacity for neurosphere formation ($P=0.011$). In vivo experiments confirmed these findings, as SeBT-treated cells formed more extensive lung metastases in nude mice compared to controls.
Discussion
The study highlights a "double-edged sword" effect of G9a inhibition. While Bix is a potent anti-cancer agent at therapeutic concentrations, chronic exposure to sub-lethal doses can inadvertently promote a more aggressive, metastatic phenotype. Interestingly, the EMT induction did not strictly correlate with H3K9 methylation levels, suggesting that Bix may influence metastasis through pathways independent of its primary epigenetic target. These results underscore the importance of maintaining consistent drug levels within the tumor microenvironment to avoid unintended promotion of cancer progression.
Summary updated